Literature DB >> 15102834

Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin.

Ghislain Delpierrre1, Didier Vertommen, David Communi, Mark H Rider, Emile Van Schaftingen.   

Abstract

Fructosamine-3-kinase (FN3K) phosphorylates fructosamine residues, leading to their destabilization and their shedding from protein. Support for the occurrence of this deglycation mechanism in intact cells has been obtained by showing that hemoglobin is significantly more glycated when human erythrocytes are incubated with an elevated glucose concentration in the presence of 1-deoxy-1-morpholinofructose (DMF), a cell-permeable inhibitor of FN3K, than in its absence. The aim of this work was to identify the fructosamine residues on hemoglobin that are removed as a result of the action of FN3K in intact erythrocytes. Highly glycated hemoglobin derived from intact human erythrocytes incubated for 48 h with 200 mm glucose and DMF was incubated in vitro with FN3K and [gamma-(32)P]ATP. After reduction of fructosamine 3-phosphates with borohydride, the protein was digested with trypsin. Peptides were separated by reversed-phase high-performance liquid chromatography, and the radioactive peaks were analyzed by mass spectrometry. Nine different modified residues were identified. These were Lys-alpha-16, Lys-alpha-61, Lys-alpha-139, Val-beta-1, Lys-beta-17, Lys-beta-59, Lys-beta-66, Lys-beta-132, and Lys-beta-144. Some (e.g. Lys-alpha-139) were readily phosphorylated to a maximal extent by FN3K in vitro whereas others (e.g. Val-beta-1) were slowly and only very partially phosphorylated. The radiolabeled peptides containing reduced fructosamine 3-phosphates bound to Lys-alpha-16, Lys-alpha-139, and Lys-beta-17 were much less abundant if the hemoglobin substrate used for the in vitro phosphorylation with FN3K and [gamma-(32)P]ATP came from erythrocytes incubated with an elevated glucose concentration in the absence of DMF, indicating that these lysine residues had been substantially deglycated in intact cells when FN3K action was unrefrained. Other residues (e.g. Val-beta-1, Lys-alpha-61) seemed to be insignificantly deglycated in intact cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102834     DOI: 10.1074/jbc.M402091200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Increased protein glycation in fructosamine 3-kinase-deficient mice.

Authors:  Maria Veiga da-Cunha; Patrick Jacquemin; Ghislain Delpierre; Catherine Godfraind; Ivan Théate; Didier Vertommen; Frédéric Clotman; Frédéric Lemaigre; Olivier Devuyst; Emile Van Schaftingen
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

2.  Reduced fructosamine-3-kinase activity and its mRNA in human distal colorectal carcinoma.

Authors:  M Notarnicola; Maria G Caruso; V Tutino; V Guerra; S Frisullo; D F Altomare; G Misciagna
Journal:  Genes Nutr       Date:  2010-02-03       Impact factor: 5.523

3.  Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions.

Authors:  Kerry J Welsh; M Sue Kirkman; David B Sacks
Journal:  Diabetes Care       Date:  2016-08       Impact factor: 19.112

Review 4.  Glycation free adduct accumulation in renal disease: the new AGE.

Authors:  Paul J Thornalley
Journal:  Pediatr Nephrol       Date:  2005-08-24       Impact factor: 3.714

5.  Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.

Authors:  Saul Genuth; Wanjie Sun; Patricia Cleary; David R Sell; William Dahms; John Malone; William Sivitz; Vincent M Monnier
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

6.  Plant ribulosamine/erythrulosamine 3-kinase, a putative protein-repair enzyme.

Authors:  Juliette Fortpied; Rita Gemayel; Vincent Stroobant; Emile van Schaftingen
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

7.  Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes.

Authors:  N Ahmed; R Babaei-Jadidi; S K Howell; P J Beisswenger; P J Thornalley
Journal:  Diabetologia       Date:  2005-06-30       Impact factor: 10.122

8.  Identification of protein-ribulosamine-5-phosphatase as human low-molecular-mass protein tyrosine phosphatase-A.

Authors:  Juliette Fortpied; Rita Gemayel; Didier Vertommen; Emile Van Schaftingen
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

Review 9.  The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.

Authors:  Jyotiska Chaudhuri; Yasmin Bains; Sanjib Guha; Arnold Kahn; David Hall; Neelanjan Bose; Alejandro Gugliucci; Pankaj Kapahi
Journal:  Cell Metab       Date:  2018-09-04       Impact factor: 27.287

10.  Association of glycation gap with mortality and vascular complications in diabetes.

Authors:  Ananth U Nayak; Alan M Nevill; Paul Bassett; Baldev M Singh
Journal:  Diabetes Care       Date:  2013-07-08       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.